Peritoneal metastasis in gynecologic cancers
Oncoinvent ASA focuses on epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma when disease has spread within the peritoneal cavity. Its research activity centers on patients with high-grade serous and high-grade endometrioid tumors with peritoneal metastasis.
- Homologous recombination proficiency
- Platinum-sensitive recurrent disease
- Peritoneal carcinomatosis
The sponsor’s clinical interest includes disease settings following cytoreductive surgery and treatment pathways involving residual or recurrent intraperitoneal cancer burden.
Colorectal carcinoma with peritoneal carcinomatosis
The sponsor also studies peritoneal carcinomatosis arising from colorectal carcinoma, with a therapeutic emphasis on disease confined to or recurring in the peritoneum. This includes patients managed after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
- Intraperitoneal disease control
- Post-surgical residual disease
- Peritoneal recurrence
Research activity in this area reflects interest in advanced abdominal malignancy where local spread within the peritoneal cavity is a major clinical concern.
Radionuclide therapy for intraperitoneal cancer
Oncoinvent ASA’s portfolio includes investigation of intraperitoneal alpha-emitting radionuclide therapy for cancers with peritoneal dissemination. The therapeutic focus is on localized treatment of malignant cells within the abdominal lining.
- Radspherin®
- Alpha-emitting radionuclide
- Intraperitoneal administration
These studies address both ovarian cancer and colorectal cancer populations with peritoneal carcinomatosis.
Postoperative and recurrent disease settings
The sponsor’s research extends across clinical settings after definitive surgery, including patients with complete surgical resection and those undergoing treatment after interval debulking surgery. The disease focus remains concentrated on recurrent or residual peritoneal metastases.
- Residual intraperitoneal disease
- Recurrent epithelial carcinoma
- Adjuvant local therapy
Clinical interest is directed toward malignancies where the peritoneum is a dominant site of spread and relapse.
